https://www.taxtmi.com/caselaws?id=422477 NAPA held that a medicine retailer violated Section 171(1) of CGST Act by failing to pass on GST rate reduction benefit from 28% to 18% effective 15.11.2017 on ECLAT SERUM. Investigation period covered 15.11.2017 to 30.09.2019. Respondent did not reduce selling prices despite tax rate reduction, resulting in profiteering of Rs. 1,54,138. Authority directed price reduction per Rule 133(3)(a) to pass benefit to recipients. No penalty imposed as penal provisions came into force from 01.01.2020 while violation period was 01.01.2019 to 30.09.2019, and respondent deposited profiteered amount with interest. Application disposed. en-us Tue, 10 May 2022 00:00:00 +0530 Thu, 03 Apr 2025 11:09:00 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=422477 NAPA held that a medicine retailer violated Section 171(1) of CGST Act by failing to pass on GST rate reduction benefit from 28% to 18% effective 15.11.2017 on ECLAT SERUM. Investigation period covered 15.11.2017 to 30.09.2019. Respondent did not reduce selling prices despite tax rate reduction, resulting in profiteering of Rs. 1,54,138. Authority directed price reduction per Rule 133(3)(a) to pass benefit to recipients. No penalty imposed as penal provisions came into force from 01.01.2020 while violation period was 01.01.2019 to 30.09.2019, and respondent deposited profiteered amount with interest. Application disposed. Case-Laws GST Tue, 10 May 2022 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=422477